title: Bone density and bone turnover marker monitoring after discontinuation of alendronate therapy: an evidence-based decision to do less.
authors.affiliation: Department of Family Medicine, University of North Carolina, Chapel Hill.
authors.forename: Margaret L
authors.initials: ML
authors.lastname: Gourlay
authors.affiliation: Department of Medicine, University of Minnesota Medical School, Minneapolis3Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis4Department of Medicine, Minneapolis VA Health Care System, Minneapolis.
authors.forename: Kristine E
authors.initials: KE
authors.lastname: Ensrud
mesh_terms: D019386:Alendronate / Q000008:administration & dosage*; D000469:Alkaline Phosphatase / Q000097:blood*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D005260:Female; D005544:Forecasting; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans
chemical_list: D050071:Bone Density Conservation Agents; D000469:Alkaline Phosphatase; D019386:Alendronate